Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...
This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...
Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback